Xenon Pharmaceuticals Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Xenon Pharmaceuticals Inc. - overview
Established
1996
Location
Burnaby, BC, Canada
Primary Industry
Pharmaceuticals
About
Based in British Columbia, Canada, and founded in 1996, Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company that develops therapeutics to treat patients with neurological disorders across Canada. In October 2021, Xenon Pharmaceuticals Inc. closed its announced underwritten public offerings of 10 million common shares and went public.
The company trades in NASDAQ under the ticker symbol XENE. Xenon Pharmaceuticals Inc. employs approximately 123 employees and Ian Mortimer is the CEO and president of the company. Xenon Pharmaceuticals Inc.
's product pipeline includes XEN496, XEN1101, XEN007, NBI-921352(Neurocrine) and FX301(Flexion). XEN1101 is the differentiated Kv7 potassium channel modulator used for the treatment of the major depressive disorder (MDD), epilepsy and other neurological disorders. XEN496 is the Kv7 potassium channel modulator used for the treatment of epileptic encephalopathy (KCNQ2-DEE) and KCNQ2 developmental. XEN007 is the CaV2.
1 Calcium Channel Modulator that is studied in treatment-resistant absence seizures in pediatric patients and other neurological disorders. NBI-921352 is the clinical stage selective Nav1. 6 sodium channel inhibitor used for the treatment of pediatric patients with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE). FX301 is used to support the administration as a peripheral nerve block for control of postoperative pain.
Current Investors
Invesco, MX Associates, LipoteRx Ltd.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Epidemiology, Pharmaceutical Research & Development
Website
www.xenon-pharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.